Aquestive Therapeutics, Inc. AQST Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$68.91M-27.1% | -$83.78M-89.8% | -$68.98M-96.0% | -$65.04M-153% | -$54.24M-88.6% | ||
| $522K-19.7% | $548K-23.7% | $565K-45.6% | $585K-48.8% | $650K-47.0% | ||
| $8.36M+17.6% | $7.62M+7.4% | $8.65M+53.5% | $7.45M+54.2% | $7.11M+81.0% | ||
| $10.53M-2.4% | $11M+2.6% | $10.95M+11.5% | $10.87M+51.0% | $10.79M+135% | ||
| —— | —— | —— | $1.16M— | -$536K— | ||
| —— | —— | —— | —— | $3.4M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | -$1.01M— | -$453K— | ||
| $39K— | -$1K— | -$33K— | -$74K— | —— | ||
| —— | —— | —— | —— | -$12.72M— | ||
| -$3.59M-265% | $10.44M+1,054% | $2.15M— | $5.87M— | $2.18M— | ||
| -$43.84M+10.1% | -$52.43M-46.6% | -$50.45M-47.5% | -$49.68M-101% | -$48.78M-90.7% | ||
| $479K+80.8% | $562K+253% | $492K+208% | $337K+45.9% | $265K-74.1% | ||
| -$479K-80.8% | -$562K-253% | -$492K-208% | -$337K-45.9% | -$265K+74.1% | ||
| —— | —— | —— | —— | $23.25K— | ||
| $1.27M— | $1.27M— | —— | —— | —— | ||
| $436K-52.1% | $810K-26.4% | $793K— | $925K— | $911K— | ||
| $86.49M+284% | $102.72M+22.9% | $102.21M+17.0% | $20.8M-77.5% | $22.51M-76.3% | ||
| —— | —— | —— | —— | —— | ||
| $6.1M-20.0% | $6.1M-14.1% | $6.11M-16.8% | $7.62M+76.8% | $7.62M+84.1% | ||
| $10.53M-2.4% | $11M+2.6% | $10.95M+11.5% | $10.87M+51.0% | $10.79M+135% | ||
| -$3.59M-265% | $10.44M+1,054% | $2.15M— | $5.87M— | $2.18M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | -$12.72M— | ||
| —— | —— | —— | -$1.01M— | -$453K— | ||
| —— | —— | —— | —— | —— | ||
| $39K— | -$1K— | -$33K— | -$74K— | —— | ||
| —— | —— | —— | —— | $8.75K+600% | ||
| —— | —— | —— | —— | $30.2M+214% | ||
| —— | —— | —— | —— | $23.25K— | ||
| —— | —— | —— | —— | —— | ||
| —— | $65K— | $48.75K— | $32.5K— | $16.25K— | ||
| —— | $0-100% | $62.5K-66.7% | $125K0.0% | $187.5K+200% | ||
| -$44.32M+9.6% | -$52.99M-47.5% | -$50.94M-48.2% | -$50.02M-101% | -$49.04M-84.3% | ||
| -$44.32M+9.6% | -$52.99M-47.5% | -$50.94M-48.2% | -$50.02M-101% | -$49.04M-84.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Aquestive Therapeutics, Inc. generate?
- Aquestive Therapeutics, Inc. (AQST) generated -$43.8M in operating cash flow over the trailing twelve months.
- What is Aquestive Therapeutics, Inc.'s free cash flow?
- After $479.0K of capital expenditures, Aquestive Therapeutics, Inc.'s free cash flow was -$44.3M over the trailing twelve months, up 9.6% year over year.
- Where does Aquestive Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Aquestive Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
